Cargando…
New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma
In the last five years, IDH1 mutations in human malignancies have significantly shaped the diagnosis and management of cancer patients. Ongoing intense research efforts continue to alter our understanding of the role of the IDH1 mutation in tumor formation. Currently, evidence suggests the IDH1 muta...
Autores principales: | Dimitrov, Lilia, Hong, Christopher S., Yang, Chunzhang, Zhuang, Zhengping, Heiss, John D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323358/ https://www.ncbi.nlm.nih.gov/pubmed/25678837 http://dx.doi.org/10.7150/ijms.11047 |
Ejemplares similares
-
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
por: Han, Sue, et al.
Publicado: (2020) -
DDRE-08. NRF2/GLUTATHIONE METABOLISM AS A NOVEL THERAPEUTIC TARGET FOR IDH1-MUTATED GLIOMA
por: Liu, Yang, et al.
Publicado: (2021) -
mTORC2/Rac1 Pathway Predisposes Cancer Aggressiveness in IDH1-Mutated Glioma
por: Liu, Yang, et al.
Publicado: (2020) -
Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins
por: Kaminska, Bozena, et al.
Publicado: (2019) -
New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma
por: Argersinger, Davis P., et al.
Publicado: (2021)